# Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)

> **NCT00457275** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 440 (—)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** MK0653, ezetimibe / Duration of Treatment: 4 Weeks

## Key facts

- **NCT ID:** NCT00457275
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 440 (—)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457275, "Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00457275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*